Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Cancer Research

• Publication date

  2010-02-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-09-2469PMID 20145183PMCID PMC2822897
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modulating Radiation Resistance by Inhibiting Ribonucleotide Reductase in Cancers with Virally or Mutationally Silenced p53 Protein

  2009cited by this paper
• Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation.

  2007cited by this paper
• Metastasis-Suppressing Potential of Ribonucleotide Reductase Small Subunit p53R2 in Human Cancer Cells

  2006cited by this paper
• In vitro and In vivo Radiosensitization Induced by the Ribonucleotide Reductase Inhibitor Triapine (3-Aminopyridine-2-Carboxaldehyde-Thiosemicarbazone)

  2006cited by this paper
• Structure, function, and mechanism of ribonucleotide reductases.

  2004cited by this paper
• A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

  2004cited by this paper
• In Vitro Characterization of Enzymatic Properties and Inhibition of the p53R2 Subunit of Human Ribonucleotide Reductase

  2004cited by this paper
• Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development.

  2004cited by this paper
• Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.

  2004cited by this paper
• Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

  2003cited by this paper
• Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.

  2003cited by this paper
• Overexpression of the R2 Subunit of Ribonucleotide Reductase in Human Nasopharyngeal Cancer Cells Reduces Radiosensitivity

  2003cited by this paper
• Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix.

  2002cited by this paper
• Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule

  2002cited by this paper
• Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.

  2001cited by this paper
• Mammalian p53R2 Protein Forms an Active Ribonucleotide Reductasein Vitro with the R1 Protein, Which Is Expressed Both in Resting Cells in Response to DNA Damage and in Proliferating Cells*

  2001cited by this paper
• Structure and function of the radical enzyme ribonucleotide reductase.

  2001cited by this paper
• Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

  2000cited by this paper
• Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

  1999cited by this paper
• Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.

  1999cited by this paper
• Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.

  1999cited by this paper
• Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

  1999cited by this paper
• Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells.

  1998cited by this paper
• Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells.

  1995cited by this paper
• Concise review: methemoglobinemia.

  1993cited by this paper
• Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial.

  1993cited by this paper
• Hemoglobin by first derivative spectrophotometry: extent of hemolysis in plasma and serum collected in vacuum container devices.

  1989cited by this paper
• Role of ribonucleotide reductase in expression in the neoplastic program.

  1981influential reference
• Measuring percent oxygen saturation of hemoglobin, percent carboxyhemoglobin and methemoglobin, and concentrations of total hemoglobin and oxygen in blood of man, dog, and baboon.

  1980cited by this paper
• Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis.

  1979cited by this paper
• Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas.

  1970cited by this paper

• Ultrasound‐Assisted Synthesis of Novel Chromone‐Based Thiosemicarbazone Derivatives as Potential Anticancer Agents and Their Apoptotic, Cell Cycle, Autophagy, Molecular Docking, and ADMET Prediction Studies

  2025cites this paper
• Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.

  2025cites this paper
• Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)

  2024influential citation
• Synthesis of 5-hydroxyisatin thiosemicarbazones, spectroscopic investigation, protein-ligand docking, and in vitro anticancer activity.

  2024cites this paper
• Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer.

  2024cites this paper
• Improving Therapies for Cervical Cancer While Working Toward Eradication.

  2023cites this paper
• Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1.

  2023cites this paper
• WITHDRAWN: Elevated glucose promotes DNA replication and cancer cell growth through pRB-E2F1

  2023cites this paper
• Combined modality including novel sensitizers in gynecological cancers

  2022cites this paper
• Ribonucleotide reductase: Implications of thiol S-nitrosylation and tyrosine nitration for different subunits.

  2022cites this paper
• Design and Synthesis of Novel Betulin Derivatives Containing Thio-/Semicarbazone Moieties as Apoptotic Inducers through Mitochindria-Related Pathways

  2021cites this paper
• In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer

  2021cites this paper
• Reversing oncogenic transformation with iron chelation

  2021cites this paper
• Harnessing microbial iron chelators to develop innovative therapeutic agents

  2021cites this paper
• Structural, spectral, electronic, and molecular docking investigations on N , N ‐dimethyl ‐2‐[( 1E )‐({[(methylsulfanyl)methanethioyl]amino}imino)methyl]aniline

  2021cites this paper
• Characteristics of recent clinical investigations into systemic therapy against cervical cancer: systematic analysis of trial details from Clinicaltrials.gov

  2021cites this paper
• Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance

  2021cites this paper
• In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine

  2020cites this paper
• Iron chelators in cancer therapy

  2020cites this paper
• Thiosemicarbazones as a Potent Anticancer Agents and Their Modes of Action.

  2020cites this paper
• Inhibiting RRM2 to enhance the anticancer activity of chemotherapy.

  2020cites this paper
• Novel Triapine Derivative Induces Copper-Dependent Cell Death in Hematopoietic Cancers.

  2019cites this paper
• Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer

  2019cites this paper
• Concentration of Fe(3+)-Triapine in BEAS-2B Cells

  2019cites this paper
• Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers

  2019cites this paper
• Pharmacodynamics of current and emerging treatments for cervical cancer

  2019cites this paper
• Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer

  2018cites this paper
• Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years.

  2018cites this paper
• Current and Future Initiatives for Radiation Oncology at the National Cancer Institute in the Era of Precision Medicine.

  2018cites this paper
• Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development

  2018cites this paper
• Triapine Radiochemotherapy in Advanced Stage Cervical Cancer

  2018cites this paper
• Chemotherapy and molecular therapy in cervical cancer.

  2018cites this paper
• Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers

  2018cites this paper
• LC–MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma

  2017cites this paper
• Selenotriapine – An isostere of the most studied thiosemicarbazone with pronounced pro-apoptotic activity, low toxicity and ability to challenge phenotype reprogramming of 3-D mammary adenocarcinoma tumors

  2017cites this paper
• Investigational drugs for the treatment of cervical cancer

  2017cites this paper
• Phase I Trial of Triapine–Cisplatin–Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers

  2017cites this paper
• Survival of Cervical Cancer Patients Presenting with Occult Supraclavicular Metastases Detected by FDG-Positron Emission Tomography/CT: Impact of Disease Extent and Treatment

  2017cites this paper
• The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy.

  2016cites this paper
• Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration.

  2016cites this paper
• Kinetico-mechanistic studies on methemoglobin generation by biologically active thiosemicarbazone iron(III) complexes.

  2016cites this paper
• Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies

  2016cites this paper
• Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair

  2016influential citation
• Enhanced targeting of mitochondrial peroxide defense by the combined use of thiosemicarbazones and inhibitors of thioredoxin reductase.

  2016cites this paper
• The associations of biological parameters with the effects of radiotherapy and cisplatin-based concurrent chemoradiotherapy in uterine cervical cancer

  2016cites this paper
• New Strategies for Multimodality Therapy in Treating Locally Advanced Cervix Cancer.

  2016cites this paper
• Determination of triapine, a ribonucleotide reductase inhibitor, in human plasma by liquid chromatography tandem mass spectrometry.

  2015cites this paper
• Antimetabolites That Interfere with Nucleic Acid Biosynthesis

  2015cites this paper
• Emerging drugs for the treatment of cervical cancer

  2015cites this paper
• Biomarkers of Nucleotide Metabolism in Cervical Cancer

  2015cites this paper
• Comparison of the Levels of Pro-Inflammatory Cytokines Released in the Vastus Lateralis Muscle of Patients with Fibromyalgia and Healthy Controls during Contractions of the Quadriceps Muscle – A Microdialysis Study

  2015cites this paper
• G2/M Cell Cycle Arrest and Tumor Selective Apoptosis of Acute Leukemia Cells by a Promising Benzophenone Thiosemicarbazone Compound

  2015cites this paper
• Triapine and a More Potent Dimethyl Derivative Induce Endoplasmic Reticulum Stress in Cancer Cells

  2014cites this paper
• Expanding horizons in iron chelation and the treatment of cancer: role of iron in the regulation of ER stress and the epithelial-mesenchymal transition.

  2014cites this paper
• Novel biological radiochemotherapy approaches in locally advanced-stage cervical cancer management.

  2014cites this paper
• Exploring the Anti-Cancer Activity of Novel Thiosemicarbazones Generated through the Combination of Retro-Fragments: Dissection of Critical Structure-Activity Relationships

  2014cites this paper
• Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2–IIIB Cervical Cancer

  2014cites this paper
• Triapine Disrupts CtIP-Mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase Inhibitors

  2014influential citation
• A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix: An NRG Oncology/Gynecologic Oncology Group Study

  2014cites this paper
• DEVELOPMENT OF A LIQUID CHROMATOGRAPHIC METHOD FOR QUANTITATIVE DETERMINATION OF TRIAPINE, A RIBONUCLEOTIDE REDUCTASE INHIBITOR, BY SPECTROPHOTOMETRIC STUDY OF TRIAPINE COMPLEXATION REACTION

  2014cites this paper
• Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia

  2014cites this paper
• Radiation Quality, Like Art, Consists in Drawing the Line Somewhere

  2013cites this paper
• Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.

  2013cites this paper
• Redox activation of Fe(III)-thiosemicarbazones and Fe(III)-bleomycin by thioredoxin reductase: specificity of enzymatic redox centers and analysis of reactive species formation by ESR spin trapping.

  2013cites this paper
• Ribonucleotide Reductase Expression in Cervical Cancer: A Radiation Therapy Oncology Group Translational Science Analysis

  2013cites this paper
• Novel Chelators for Cancer Treatment: Where Are We Now?

  2013influential citation
• Targeting ribonucleotide reductase for cancer therapy

  2013cites this paper
• Triapine and a more potent dimethyl derivative induce ER stress in cancer cells

  2013cites this paper
• Development of quantitative bioanalytical methods for the pharmacological studies of anti-cancer drugs

  2013cites this paper
• A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.

  2012cites this paper
• Gallium-containing anticancer compounds.

  2012cites this paper
• Elevated Ribonucleotide Reductase Levels Associate With Suppressed Radiochemotherapy Response in Human Cervical Cancers

  2012cites this paper
• Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia.

  2012cites this paper
• Emerging drugs for cervical cancer

  2012cites this paper
• STRUCTURAL AND BIOCHEMICAL STUDIES OF RIBONUCLEOTIDE REDUCTASE INHIBITION BY dATP AND Sml1

  2012cites this paper
• Ribonucleotide Reductase Inhibitors: A New Look at an Old Target for Radiosensitization

  2012cites this paper
• Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer.

  2012cites this paper
• Methemoglobin Formation by Triapine, Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and Other Anticancer Thiosemicarbazones: Identification of Novel Thiosemicarbazones and Therapeutics That Prevent This Effect

  2012cites this paper
• dNTP Supply Gene Expression Patterns after P53 Loss

  2012cites this paper
• A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study

  2012influential citation
• Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study

  2012cites this paper
• Microwave assisted synthesis and solid-state characterization of lithocholyl amides of isomeric aminopyridines.

  2011cites this paper
• Reduced Level of Ribonucleotide Reductase R2 Subunits Increases Dependence on Homologous Recombination Repair of Cisplatin-Induced DNA Damage

  2011cites this paper
• Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose rates.

  2011cites this paper
• Prevention of central nervous system relapses in diffuse large B-cell lymphoma: which patients and how?

  2011cites this paper
• Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds

  2011cites this paper
• Chelators to the rescue: different horses for different courses!

  2011cites this paper
• Molecular Strategies of Deoxynucleotide Triphosphate Supply Inhibition Used in the Treatment of Gynecologic Malignancies.

  2011cites this paper
• The iron-chelating drug triapine causes pronounced mitochondrial thiol redox stress.

  2011cites this paper
• A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo.

  2011cites this paper
• Reduced Level of Ribonucleotide Reductase R2 Subunits Increases Dependence on Homologous Recombination Repair of Cisplatin-Induced DNA Damage

  2011cites this paper
• Deoxynucleoside Salvage Facilitates DNA Repair During Ribonucleotide Reductase Blockade in Human Cervical Cancers

  2011cites this paper
• Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy

  2011cites this paper
• Chemoradiotherapy for Cervical Cancer in 2010

  2011cites this paper
• Reduced Level of Ribonucleotide Reductase R2 Subunits Increases Dependence on Homologous Recombination Repair of Cisplatin-Induced DNA Damage Molecular Fast

  2011cites this paper
• Bibliography. Lymphoma. Current world literature.

  2011cites this paper
• Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer

  2011cites this paper
• Ribonucleotide Reductase Inhibition Enhances Chemoradiosensitivity of Human Cervical Cancers

  2010cites this paper
• Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group study.

  2010cites this paper
• New Paradigms in the Treatment of Cervical Cancer

  year unknowncites this paper